FrancophonIA/ELRC3.0 huggingface dataset:
English: Lactose monohydrate Microcrystalline cellulose Sodium starch glycolate Colloidal anhydrous silica Magnesium stearate
Croatian: Jezgra tablete laktoza hidrat celuloza, mikrokristalična natrijev škroboglikolat silicijev dioksid, koloidni, bezvodni magnezijev stearat
English: Caution should be exercised and a reduction of the starting dose of Iclusig to 30 mg should be considered with concurrent use of strong CYP3A inhibitors such as clarithromycin, indinavir, itraconazole,
Croatian: Treba biti oprezan i razmotriti smanjenje početne doze lijeka Iclusig na 30 mg kod istovremene primjene s jakim inhibitorima CYP3A kao što su klaritromicin, indinavir, itrakonazol, ketokonazol, nefazodon, nelfinavir, ritonavir, sakvinavir, telitromicin, troleandomicin, vorikonazol i sok grejpfruta.
English: • a history of bleeding issues
Croatian: • anamnezu problema s krvarenjem
English: The secondary efficacy endpoints in AP-CML and BP-CML/Ph+ ALL were MCyR and MMR.
Croatian: Sekundarni ishodi za bolesnike u ubrzanoj fazi KML i blastičnoj fazi KML/Ph+ ALL bili su MCyR i MMR.
English: approximately 87% of the radioactive dose is recovered in the faeces and approximately 5% in the urine.
Croatian: Nakon pojedinačne doze [14C]-označenog ponatiniba, približno 87% radioaktivne doze odstranjuje se fecesom, a približno 5% mokraćom.
English: Ponatinib elicited tumour shrinkage and prolonged survival in mice bearing tumours expressing native or T315I mutant BCR-ABL.
Croatian: Ponatinib je izazvao smanjenje tumora i produljeno preživljavanje miševa s T315I BCR-ABL mutacijom ili bez nje.
English: The primary efficacy endpoint in AP-CML and BP-CML/Ph+ ALL was major haematological response (MaHR), defined as either a complete haematological response (CHR) or no evidence of leukaemia (NEL).
Croatian: Primarni ishod za bolesnike u ubrzanoj fazi KML i blastičnoj fazi KML/Ph+ALL bio je značajan hematološki odgovor (MaHR) definiran bilo kao kompletni hematološki odgovor (CHR, engl. complete haematological response) ili nema dokaza leukemije.
English: Neutropenia (ANC decreased)
Croatian: Neutropenija (smanjeni ABN)
English: A benefit -risk consideration should guide a decision to restart Iclusig therapy (see sections 4.2 and 4.8).
Croatian: Odluka za ponovno uvođenje terapije Iclusigom mora biti vođena razmatranjem omjera koristi i rizika (vidjeti dio 4.2 i 4.8).
English: A break in treatment or a decrease in dose may be required when lipase is increased.
Croatian: U slučaju povišenih vrijednosti serumske lipaze, možda će biti potrebno napraviti stanku u liječenju ili smanjiti dozu.
English: Cardiovascular status should continue to be monitored and medical and supportive therapy for conditions that contribute to cardiovascular risk should be optimised during treatment with ponatinib.
Croatian: Tijekom liječenja ponatinibom mora se nastaviti pratiti kardiovaskularno stanje i optimizirati medicinsko i suportivno liječenje za stanja koja doprinose kardiovaskularnom riziku .
English: The bottle contains one sealed plastic canister containing molecular sieve desiccant.
Croatian: Boca sadrži jedan plastični zatvoreni spremnik s molekularnim sitom kao sredstvom za sušenje.
English: • diarrhoea, vomiting, constipation, nausea
Croatian: • proljev, povraćanje, zatvor, mučnina
English: Table 8 Efficacy of Iclusig in resistant or intolerant Ph+ ALL patients Overall (N=32)
Croatian: Tablica 8 Djelotvornost lijeka Iclusig u bolesnika s bolesnika s Ph+ ALL koji su rezistentni ili ne podnose lijek
English: Very common headache, dizziness
Croatian: Vrlo često glavobolja, omaglica
English: White, biconvex, round film-coated tablet that is approximately 9 mm in diameter, with "AP4" debossed on one side.
Croatian: Bijela, bikonveksna okrugla filmom obložena tableta, promjera oko 9 mm s oznakom "AP4" utisnutom na jednoj strani.
English: Serious side effects (common: affects 1 to 10 users in 100):
Croatian: Ozbiljne nuspojave (često: javljaju se u 1 do 10 korisnika na 100)
English: Important adverse reactions
Croatian: Važne nuspojave
English: Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events.
Croatian: Ti su se štetni događaji javili u bolesnika sa i bez kardiovaskularnih čimbenika rizika, uključujući bolesnike u dobi od 50 godina ili mlađe.
English: The bottle contains one sealed canister containing molecular sieve desiccant.
Croatian: Boca sadrži jedan zatvoreni spremnik s molekularnim sitom kao sredstvom za sušenje.
English: Leukopenia (WBC decreased)
Croatian: Leukopenija (snižen broj Lkc)
English: Serious arterial cardiovascular, cerebrovascular, and peripheral vascular occlusive adverse reactions (treatment-emergent frequencies) occurred in 6.7%, 5.6%, and 5.1% of Iclusig treated patients, respectively.
Croatian: Ozbiljne nuspojave arterijske kardiovaskularne, cerebrovaskularne i periferne vaskularne okluzije (učestalost nuspojava izazvanih liječenjem) javile su se u 6,7%, 5,6%, odnosno 5,1 % bolesnika liječenih Iclusigom.
English: White, biconvex, round film-coated tablet that is approximately 6 mm in diameter, with "A5" debossed on one side.
Croatian: Bijela, bikonveksna okrugla filmom obložena tableta, promjera oko 6 mm s oznakom "A5" utisnutom na jednoj strani.
English: Iclusig 15 mg film-coated tablets Iclusig 45 mg film-coated tablets
Croatian: Iclusig 15 mg filmom obložene tablete Iclusig 45 mg filmom obložene tablete ponatinib
English: • had a prior heart attack or stroke
Croatian: • preboljeli srčani ili moždani udar
English: (95% CI) a Primary endpoint for AP-CML and BP-CML/Ph+ ALL Cohorts was MaHR, which combines complete haematological responses and no evidence of leukaemia.
Croatian: (95% CI) a Primarni ishod za kohorte s AP-KML i BP-KML/Ph+ ALL bio je MaHR što kombinira kompletni hematološki odgovori i bez dokaza leukemije.
English: (95% CI) Major Molecular Response b
Croatian: (95% CI) Značajan citogenetski odgovorc
English: Haupt Pharma - AMAREG GmbH Donaustaufer Strasse 378 D-93055 Regensburg Germany
Croatian: Haupt Pharma - AMAREG GmbH Donaustaufer Strasse 378
English: Very common bone pain, arthralgia, myalgia, pain in extremity, back pain, muscle spasms
Croatian: Vrlo često bol u kostima, artralgije, mijalgije, bol u udovima, bol u leđima, spazmi mišića
English: Vascular occlusion
Croatian: Vaskularna okluzija
English: Serious venous occlusive reactions (treatment-emergent frequencies) occurred in 4.5% of patients.
Croatian: Ozbiljne nuspojave venske okluzije (učestalost nuspojava izazvanih liječenjem) javile su se u 4,5% bolesnika.
English: In a study in rats, diffuse corneal edema with neutrophilic cell infiltration, and hyperplastic changes in the lenticular epithelium suggestive of a mild phototoxic reaction were observed in animals treated with 5 and 10 mg/kg ponatinib
Croatian: U studijama na štakorima kod doza od 5 i 10 mg/kg ponatiniba uočeni su difuzni edem rožnice s infiltracijom neutrofilnih stanica i hiperplastične promjene u epitelu leće što ukazuje na blage fototoksične reakcije.
English: Patients may require urgent clinical intervention for hypertension associated with confusion, headache, chest pain, or shortness of breath.
Croatian: Za hipertenziju povezanu sa zbunjenošću, glavoboljom, boli u prsima ili nedostatkom zraka bolesnicima može biti potrebna hitna klinička intervencija.
English: Substances that may have their serum concentrations altered by ponatinib
Croatian: Tvari čija se koncentracija u serumu mijenja pod utjecajem ponatiniba
English: Do not swallow the desiccant canister.
Croatian: Nemojte progutati spremnik sa sredstvom za sušenje.
English: Common pancytopenia, febrile neutropenia, white blood cell count decreased
Croatian: Često pancitopenija, febrilna neutropenija, smanjen broj leukocita
English: ANC ≥ 1.5 x 109/L and platelet ≥ 75 x 109/L
Croatian: ≥ 75 x 109/l
English: Venous occlusive reactions (treatment-emergent frequencies) occurred in 5.0% of patients.
Croatian: Nuspojave venske okluzije (učestalost nuspojava izazvanih liječenjem) javile su se u 5,0 % bolesnika.
English: • Withhold Iclusig and resume at 30 mg after recovery to
Croatian: • Obustavite terapiju lijekom Iclusig i nastavite s 30 mg nakon oporavka na < stupanj 2
English: MARKETING AUTHORISATION NUMBER(S) EU/1/13/839/001
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/13/839/001
English: • hot flush, flushing
Croatian: • navale vrućine, naleti crvenila
English: (95% CI) Major Cytogenetic Responsec
Croatian: (95% CI) Značajan citogenetički odgovorc
English: NAME OF THE MEDICINAL PRODUCT Iclusig 15 mg film-coated tablets
Croatian: NAZIV LIJEKA Iclusig 15 mg filmom obložene tablete
English: Very common anaemia, platelet count decreased, neutrophil count decreased
Croatian: Vrlo često anemija, smanjenje broja trombocita, smanjenje broja neutrofila
English: - pancreas inflammation.
Croatian: - upala gušterače.
English: Phosphorus decreased
Croatian: Snižen fosfor
English: Common side effects (affects 1 to 10 users in 100):
Croatian: Česte nuspojave (javljaju se u 1 do 10 korisnika na 100)
English: Treatment-emergent hypertension occurred in Iclusig-treated patients.
Croatian: U bolesnika liječenih Iclusigom javila se hipertenzija izazvana liječenjem.
English: Ponatinib is a potent pan BCR-ABL inhibitor with structural elements, including a carbon-carbon triplebond, that enable high affinity binding to native BCR-ABL and mutant forms of the ABL kinase.
Croatian: Zahvaljujući strukturi koja uključuje i trostruku vezu između atoma ugljika ponatinib ima visoki afinitet vezivanja za divlji tip BCR-ABL i mutirane ABL kinaze.
English: • chills, flu-like illness
Croatian: • zimica, bolest nalik gripi
English: NAME OF THE MEDICINAL PRODUCT Iclusig 45 mg film-coated tablets
Croatian: NAZIV LIJEKA Iclusig 45 mg filmom obložene tablete
English: T315I Cohort (N=64)
Croatian: T315I kohorta (N=64)
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 15 mg of ponatinib (as hydrochloride).
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV Svaka filmom obložena tableta sadrži 15 mg ponatiniba (u obliku ponatinibklorida).
English: Close clinical surveillance is recommended when ponatinib is administered with these medicinal products.
Croatian: Preporučuje se pomno praćenje bolesnika koji uz ponatinib primaju i navedene lijekove.
English: Sodium decreased
Croatian: Snižen natrij
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 45 mg of ponatinib (as hydrochloride).
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV Svaka filmom obložena tableta sadrži 45 mg ponatiniba (u obliku ponatinibklorida).
English: Haematologic support such as platelet transfusion and haematopoietic growth factors can be used during treatment if clinically indicated.
Croatian: Ukoliko je to klinički indicirano, mogu se primjenjivati suportivne mjere liječenja kao što su transfuzije trombocita i hematopoetskih čimbenika rasta.
English: Uncommon side effects (affects 1 to 10 users in 1,000):
Croatian: Manje česte nuspojave (javljaju se u 1 do 10 korisnika na 1000)
English: • Withhold Iclusig and resume at 15 mg after recovery to
Croatian: • Obustavite terapiju lijekom Iclusig i nastavite s 15 mg nakon oporavka na < stupanj 2
English: Table 6 Efficacy of Iclusig in resistant or intolerant chronic phase CML patients Overall (N=267)
Croatian: Tablica 6 Djelotvornost lijeka Iclusig u bolesnika u kroničnoj fazi KML koji su rezistentni ili intolerantni
English: Ponatinib is not displaced by concomitant administration of ibuprofen, nifedipine, propranolol, salicylic acid, or warfarin.
Croatian: Istovremena primjena ibuprofena, nifedipina, propranolola, salicilatne kiseline, ili varfarina ne istiskuje ponatinib iz veze s proteinima plazme.
English: T315I Cohort (N=18)
Croatian: T315I kohorta (N=18)
English: Common vision blurred, dry eye, periorbital oedema, eyelid oedema
Croatian: Često zamagljeni vid, suhe oči, periorbitalni edem, edem očnog kapka
English: Based on the Kaplan-Meier estimates, 87% (95% CI: [78%-92%]) of CP-CML (median duration of treatment: 866 days) patients who achieved a MCyR and 66% (95% CI: [55%- 75%]) of CP-CML patients who achieved a MMR are projected to maintain that response at 24 months.
Croatian: U vrijeme podnošenja ažuriranog izvješća s praćenjem svih uključenih bolesnika tijekom najmanje 27 mjeseci, medijan trajanja MCyR i MMR još nije bio dosegnut Temeljem Kaplan-Meierovih analiza predviđa se da će 87% (95% CI: [78%-92%]) bolesnika u kroničnoj fazi KML (medijan trajanja liječenja: 866 dana) koji su postigli MCyR i 66% (95% CI: [55%- 75%]) bolesnika u kroničnoj fazi KML koji su postigli MMR održati postignuti odgovor nakon 24 mjeseca.
English: Haemorrhage
Croatian: Hemoragija
English: T315I Cohort (N=22)
Croatian: T315I kohorta (N=22)
English: T315I Cohort (N=24)
Croatian: T315I kohorta (N=24)
English: Very common dyspnoea, cough
Croatian: Vrlo često dispneja, kašalj
English: • St. John's wort: a herbal product used to treat depression.
Croatian: • Gospina trava: biljni lijek za liječenje depresije.
English: • diarrhoea
Croatian: • Dojenje
English: No Dose Reduction Dose reduction to 30 mg only ≥ 90 day reduction at 30 mg ≥ 180 day reduction at 30 mg ≥ 360 day reduction at 30 mg Any dose reduction to 15 mg ≥ 90 day reduction at 15 mg ≥ 180 day reduction at 15 mg ≥ 360 day reduction at 15 mg
Croatian: ≥ 360 dana smanjenje na 15 mg
English: Each 45 mg film-coated tablet contains 45 mg ponatinib (as ponatinib hydrochloride).
Croatian: Svaka filmom obložena tableta od 45 mg sadrži 45 mg ponatiniba (u obliku ponatinibklorida).
English: Each 15 mg film-coated tablet contains 15 mg ponatinib (as ponatinib hydrochloride).
Croatian: Svaka filmom obložena tableta od 15 mg sadrži 15 mg ponatiniba (u obliku ponatinibklorida).
English: NAME OF THE MEDICINAL PRODUCT Iclusig 45 mg film-coated tablets Ponatinib
Croatian: Iclusig 45 mg filmom obložene tablete ponatinib
English: (95% CI) a Primary endpoint for CP-CML Cohorts was MCyR, which combines both complete (No detectable Ph+
Croatian: (95% CI) a Primarni ishod za kohorte u kroničnoj fazi KML bio je MCyR, koji kombinira i kompletne (stanice
English: In cynomolgus monkeys, thyroid gland follicular atrophy mostly accompanied by a reduction in T3 levels and a tendency toward increased TSH levels were observed in the 4-week repeat-dose toxicity study in cynomolgus monkeys.
Croatian: U četverotjednoj studiji toksičnosti ponovljene doze u makaki majmuna, uočena je folikularna atrofija štitne žlijezde praćena sniženom razinom hormona T3 i povećanom sklonosti porasta TSH.
English: Uncommon hepatotoxicity, jaundice
Croatian: Manje često hepatoksičnost, žutica
English: Uncommon retinal vein thrombosis, retinal vein occlusion, retinal artery occlusion, visual impairment
Croatian: Manje često tromboza vene mrežnice, okluzija vene mrežnice, okluzija arterije mrežnice, smetnje vida
English: NAME OF THE MEDICINAL PRODUCT Iclusig 15 mg film-coated tablets Ponatinib
Croatian: Iclusig 15 mg filmom obložene tablete ponatinib
English: Serious bleeding events and haemorrhage, including fatalities, occurred in Iclusig-treated patients.
Croatian: U bolesnika liječenih Iclusigom zabilježeni su ozbiljni događaji krvarenja i hemoragije, uključujući i smrtne slučajeve.
English: - decreased number of white blood cells called neutrophilis (symptoms include: increase tendency of infection)
Croatian: • promjene koncentracija u krvi: smanjeni broj crvenih krvnih stanica (simptomi uključuju: slabost, omaglicu, umor) smanjeni broj trombocita (simptomi uključuju: povećanu sklonost krvarenju i nastajanju modrica) smanjeni broj bijelih krvnih stanica zvanih neutrofili (simptomi uljučuju: povećanu sklonost infekcijama) povišena razina serumskog proteina zvanog lipaza
English: Thrombocytopenia (platelet count decreased)
Croatian: Trombocitopenija (snižen broj trombocita)
English: Women of childbearing age being treated with Iclusig should avoid becoming pregnant.
Croatian: • Kontracepcijski savjeti za muškarce i žene Ženama reproduktivne dobi koje se liječe lijekom Iclusig se ne preporučuje trudnoća.
English: • Withhold Iclusig and resume at 30 mg after recovery to < Grade 2 Recurrence at 30 mg:
Croatian: 30 mg nakon oporavka na ≤ stupanj 1 (< 1,5 x IGGN) Ponovna pojava uz 30 mg:
English: • pancreas inflammation.
Croatian: • upala gušterače.
English: Ponatinib
Croatian: • proljev
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 15 mg ponatinib (as hydrochloride).
Croatian: TVARI Svaka filmom obložena tableta sadrži 15 mg ponatiniba (u obliku ponatinibklorida).
English: • Breast-feeding Stop breast-feeding during treatment with Iclusig.
Croatian: • Obustaviti terapiju lijekom Iclusig i nastaviti s dozom od
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 45 mg ponatinib (as hydrochloride).
Croatian: TVARI Svaka filmom obložena tableta sadrži 45 mg ponatiniba (u obliku ponatinibklorida).
English: ANC ≥ 1.5 x 109/L and platelet ≥ 75 x 109/L Second occurrence:
Croatian: 45 mg nakon oporavka ABN na ≥ 1,5 x 109/l te trombocita na
English: Do not eat, drink or smoke while handling the product.
Croatian: Nemojte jesti, piti ni pušiti dok rukujete proizvodom.
English: Date of first authorisation: 18/08/2017
Croatian: Datum prvog odobrenja: 18/08/2017
English: ATCvet code: QP53BE02.
Croatian: ATCvet kod: QP53BE02
English: This activity breaks the mite life cycle.
Croatian: Ta aktivnost zaustavlja životni ciklus tekuti.
English: Eggs: zero days.
Croatian: Jaja: nula dana.
English: This procedure should be repeated on each day of administration.
Croatian: Taj postupak treba ponavljati svakog dana primjene proizvoda.
English: EXP {month/year} Once opened, use within 1 year.
Croatian: EXP {mjesec/godina} Jednom otvoren, upotrijebiti unutar jedne godine.
English: Fluralaner is highly bound to protein.
Croatian: Fluralaner se čvrsto veže uz proteine.
English: The excipients listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Croatian: Pomoćne tvari navedene u dijelu 6.1 SPC su ili dozvoljene tvari za koje je u tablici 1, Dodatka Uredbe Komisije (EU) br. 37/2010 navedeno da određivanje MRL nije nužno ili se smatra da se na njih ne primjenjuju odredbe Uredbe (EZ) br. 470/2009 kada se primjenjuju u tim veterinarsko medicinskim proizvodima.
English: If the product is spilled, remove any affected clothes.
Croatian: Ako prolijete proizvod, skinite smočenu odjeću.
English: The product can be used during lay.
Croatian: Proizvod se može koristiti tijekom nesenja.
English: 5831 AN Boxmeer The Netherlands
Croatian: 5831 AN Boxmeer
English: Exzolt should not enter water courses as this may be dangerous for aquatic invertebrates.
Croatian: Exzolt ne smije ući u vodotokove jer to može biti opasno po vodene beskralježnjake.
English: The product should be added to a volume of water that the chickens will consume in one day.
Croatian: Proizvod se dodaje u količinu vode koju će kokoši popiti u jednom danu.
English: After oral administration, fluralaner is absorbed rapidly from the medicated drinking water, reaching maximum plasma concentrations 36 hours after the first dose and 12 hours after the second dose.
Croatian: Nakon peroralne primjene fluralaner se brzo apsorbira iz vode za piće s proizvodom te postiže maksimalne koncentracije u plazmi 36 sati nakon prve doze i 12 sati nakon druge doze.
English: Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
Croatian: Ne koristite veterinarsko-medicinski proizvod nakon isteka roka valjanosti naznačenog na etiketi nakon skraćenice za rok valjanosti EXP.
English: If another course of treatment is indicated, the interval between two courses of treatment should be at least 3 months.
Croatian: Ukoliko je indiciran i drugi ciklus tretiranja, interval između dva ciklusa mora biti najmanje 3 mjeseca.
English: This period of time must be long enough to allow all the birds to receive the required dose.
Croatian: To razdoblje mora biti dovoljno dugo da bi kokoši primile potrebnu dozu.
English: Alpha-tocopherol (all-rac-α-tocopherol) Diethylene glycol monoethyl ether Polysorbate 80
Croatian: Alfa-tokoferol (sav-rac-α-tokoferol) Dietilen glikol monoetilni eter Polisorbat 80
English: Muscle Skin and fat in natural proportions Liver
Croatian: Mišićje Koža i masno tkivo u prirodnim omjerima Jetra
English: • Make sure the dosing pump is properly set to deliver the medicated water during the predetermined treatment period (hours).
Croatian: • Provjerite je li pumpa za doziranje pravilno postavljena za dovođenje vode s proizvodom tijekom utvrđenog razdoblja tretiranja (u satima).
English: Estimate how much water birds will consume during treatment based on the previous day's water consumption.
Croatian: Procijenite koliko će vode kokoši popiti tijekom tretiranja na temelju potrošnje prethodnog dana.
English: Fluralaner is widely distributed throughout the body, with the highest concentrations reported in the liver and skin/fat.
Croatian: Fluralaner se rasprostranjuje po čitavom tijelu, uz najviše koncentracije zabilježene u jetri i koži/masnom tkivu.
English: The apparent elimination half-life is approximately 5 days following oral administration.
Croatian: Procijenjeni poluvijek eliminacije približno je 5 dana nakon peroralne primjene.
English: Bottle of 50 ml, 1 litre or 4 litres.
Croatian: Boca od 50 ml, 1 litre ili 4 litre.
English: Once diluted use within 24 hours.
Croatian: Jednom razrijeđen upotrijebiti unutar 24 sata.
English: The treatment kills mites feeding on treated chickens and stops egg production from female mites for 15 days after the first administration of the product.
Croatian: Tretiranje ubija tekut koja se hrani na tretiranim kokošima i zaustavlja proizvodnju jajašaca ženki tekuti na 15 dana od prve primjene proizvoda.
English: The bioavailability is high, with approximately 91% of the dose absorbed following oral administration.
Croatian: Bioraspoloživost je visoka te se približno 91 % doze apsorbira nakon peroralne primjene.
English: The required volume of product for each treatment day is calculated from the total body weight (kg) of the entire group of chickens to be treated:
Croatian: Potrebna količina proizvoda za svaki dan tretiranja izračunava se iz ukupne tjelesne mase (kg) cijele skupine kokoši koje tretirate:
English: Avoid contact with skin, eyes and mucous membranes.
Croatian: Izbjegavajte dodir s kožom, očima i sluznicama.
English: The complete course of treatment must be administered for a full therapeutic effect.
Croatian: Za potpuni terapijski učinak potrebno je primijeniti cijeli ciklus tretiranja.
English: After each treatment administration, fill the stock solution container with clean (unmedicated) water to rinse the water lines.
Croatian: Nakon svakog tretiranja, spremnik sa zalihom otopine napunite čistom vodom (bez proizvoda) da biste isprali cijevi za vodu.
English: Colourless high density polyethylene (HDPE) bottle closed with an aluminium/polyester foil seal and a blue child-resistant polypropylene screw cap (1 litre and 4 litre presentations) or type III amber glass bottle with a white polypropylene/polyethylene (PP/PE) child-proof screw cap with expanded low density PE/aluminium foil/ PE faced liner (50 ml presentation).
Croatian: Bezbojne boce od polietilena visoke gustoće (HDPE) zatvorene brtvom od aluminijsko-poliesterske folije i plavim polipropilenskim čepom s navojem sa sigurnosnim zatvaračem (boce od 1 i 4 litre) ili staklene boce jantarne boje tipa III s bijelim polipropilenskim/polietilenskim (PP/PE) čepom s navojem sa sigurnosnim zatvaračem presvučene aluminijskom folijom niske gustoće PE/aluminijska folija/PE (pakiranja od 50 ml).
English: In case of eye contact, immediately rinse thoroughly with water.
Croatian: Ako proizvod dođe u dodir s očima, odmah ih temeljito isperite vodom.
English: No other source of drinking water should be available during the medication period.
Croatian: Tijekom razdoblja primjene proizvoda ne smije biti dostupan nijedan drugi izvor vode za piće.